PROVAYBLUE (methylene blue) injection, USP: full prescribing information (2024)

Government Record · American Regent, Inc. / U.S. Food and Drug Administration · January 2024

American Regent et al., 2024-01: The FDA label for the only approved methylene blue injection carries a boxed warning for serious or fatal serotonin syndrome with serotonergic drugs and opioids, and contraindicates the drug in G6PD deficiency because of haemolytic anaemia.

PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids.

p. 1 (boxed warning)

American Regent et al., 2024-01: The FDA label for the only approved methylene blue injection carries a boxed warning for serious or fatal serotonin syndrome with serotonergic drugs and opioids, and contraindicates the drug in G6PD deficiency because of haemolytic anaemia. Excerpt is prose from the boxed warning on page 1. Additional label facts for the record: contraindicated in severe hypersensitivity and in glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolytic anaemia (p. 1-2); may cause haemolytic anaemia requiring transfusion (5.4); interferes with pulse oximetry, causing underestimation of oxygen saturation (5.5); interferes with bispectral index monitoring; approved indication is acquired methemoglobinemia only, at 1 mg/kg IV (2.1). Holder: American Regent. This is the regulatory record of harm at clinical doses and the reason methylene blue is not a supplement in the ordinary sense. Study type: regulatory record.